President Joe Biden (AP Images)

How will the Biden ad­min­is­tra­tion af­fect fund­ing for life sci­ence re­search?

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship and Amber Tong.

The ad­vent of a new ad­min­is­tra­tion in Wash­ing­ton of­ten por­tends ma­jor changes in bud­get­ing and spend­ing, and thus it will be in the ad­min­is­tra­tion of Joe Biden, if he ad­heres to the 2020 De­mo­c­ra­t­ic Par­ty plat­form.

But one thing that is not like­ly to change is the on­go­ing uptick in fund­ing for re­search in the life sci­ences — par­tic­u­lar­ly the fund­ing for the Na­tion­al In­sti­tutes of Health, the Cen­ters for Dis­ease Con­trol, and oth­er fed­er­al agen­cies fo­cused on life sci­ence re­search.

The rea­son for that is sim­ple: Covid-19 is still with us, and based on re­cent num­bers, it shows no sign of leav­ing any­time soon — de­spite the de­vel­op­ment of vac­cines by Pfiz­er, Mod­er­na, and oth­er phar­ma­ceu­ti­cal com­pa­nies. In a speech on the week­end pri­or to his in­au­gu­ra­tion, Biden said that it was his goal “to help re­store faith in Amer­i­ca’s place in the fron­tier of sci­ence and dis­cov­ery.” Sci­ence, he added, “is dis­cov­ery … it’s about hope.”

And while politi­cians — whether they be city coun­cil mem­bers or pres­i­dents — are known for their hy­per­bol­ic de­c­la­ra­tions that don’t al­ways lead some­where, Biden is not an un­known quan­ti­ty. As a mem­ber of the Sen­ate for decades, he has an eas­i­ly-ex­am­ined record on mat­ters of all kinds, in­clud­ing life sci­ence fund­ing and re­search.

Ac­cord­ing to med­ical jour­nal The Lancet, Biden “has had a long-stand­ing in­ter­est in med­ical re­search.” As Vice Pres­i­dent un­der Barack Oba­ma, he was in charge of the ad­min­is­tra­tion’s Can­cer Moon­shot Task Force, which “brought a new ur­gency to the Fed­er­al gov­ern­ment ef­forts to fight can­cer, and forged new part­ner­ships and cre­at­ed new pro­grams and poli­cies.” A re­port is­sued at the end of the ad­min­is­tra­tion’s term shows that sig­nif­i­cant progress was made in mar­shal­ing re­sources, both pub­lic and pri­vate, to “achieve a decade’s worth of progress in five years” in the fight against can­cer.

With a pan­dem­ic still rag­ing, Biden has pledged to bring the same com­mit­ment to fight­ing Covid-19 — in which he promis­es “a de­ci­sive pub­lic health re­sponse” that in­cludes de­vel­op­ment of vac­cines, fund­ing for its dis­tri­b­u­tion, and “the full de­ploy­ment and op­er­a­tion of nec­es­sary sup­plies, per­son­nel, and fa­cil­i­ties.”

If Biden does in­deed in­crease bud­gets for life sci­ence re­search, he will be fol­low­ing in a decades-strong tra­di­tion. The bud­get for the NIH, for ex­am­ple, has near­ly quadru­pled since 1995, grow­ing every year, in­clud­ing in 2021; in its bud­get for this year, Con­gress ap­proved a 3% in­crease in the agency’s fund­ing, with the to­tal al­lo­ca­tion for the year at $42.9 bil­lion, $1.25 bil­lion more than the 2020 lev­el.

Last year, the NIH award­ed 10 grants for the es­tab­lish­ment of the first-ever Cen­ters for Re­search in Emerg­ing In­fec­tious Dis­eases (CREID), a “glob­al net­work will in­volve mul­ti­dis­ci­pli­nary in­ves­ti­ga­tions in­to how and where virus­es and oth­er pathogens emerge from wildlife and spillover to cause dis­ease in peo­ple.”

That ini­tia­tive is a sign of things to come; the Covid-19 pan­dem­ic has raised con­cerns among sci­en­tists that hu­man­i­ty could see a rise in zoonot­ic dis­eases, re­sult­ing in even greater pub­lic health threats in the years to come.

One of the lessons of the pan­dem­ic is that we can­not rest on our lau­rels when it comes to health­care re­search. Along with pre­vent­ing pan­demics, the NIH will con­tin­ue fund­ing the many oth­er ar­eas in which it is ac­tive, in­clud­ing can­cer re­search, ar­ti­fi­cial in­tel­li­gence, Alzheimer’s treat­ment, etc. That fund­ing will go to uni­ver­si­ties, star­tups, phar­ma­ceu­ti­cal firms, and oth­er or­ga­ni­za­tions that are do­ing deep-dive re­search in all these ar­eas.

While much of that fund­ing goes to aca­d­e­m­ic re­search, the NIH pro­vides bil­lions of dol­lars an­nu­al­ly for small life sci­ence re­search firms, who are at the fore­front of de­vel­op­ing sci­en­tif­ic ini­tia­tives in­to prod­ucts and ser­vices that will help solve some of our most press­ing health prob­lems.

In fact, it was such non-di­lu­tive gov­ern­ment fund­ing that en­abled the phar­ma­ceu­ti­cal firms to quick­ly de­vel­op the Covid-19 vac­cines, based on the use of mR­NA tech­nol­o­gy to en­able the de­vel­op­ment of an­ti­bod­ies to the virus. That tech­nol­o­gy has been around for years, based on re­search con­duct­ed by small and start­up biotech firms and labs stretch­ing back decades.

An­oth­er les­son learned from Covid-19: Lis­ten to the sci­ence. The vac­cines are the re­sult of years of re­search and ex­ten­sive col­lab­o­ra­tion be­tween sci­en­tists all over the world, and that col­lab­o­ra­tion suc­ceed­ed. If that ap­proach was able to bring a so­lu­tion to one of the biggest prob­lems we’ve faced in mod­ern times, it can help solve many oth­er prob­lems, too — and there is no doubt that the new ad­min­is­tra­tion will ap­ply that Covid-in­duced les­son to oth­er prob­lems, too.

Ram May-Ron is a man­ag­ing part­ner at Free­Mind.

The DCT-OS: A Tech­nol­o­gy-first Op­er­at­ing Sys­tem - En­abling Clin­i­cal Tri­als

As technology-enabled clinical research becomes the new normal, an integrated decentralized clinical trial operating system can ensure quality, deliver consistency and improve the patient experience.

The increasing availability of COVID-19 vaccines has many of us looking forward to a time when everyday things return to a state of normal. Schools and teachers are returning to classrooms, offices and small businesses are reopening, and there’s a palpable sense of optimism that the often-awkward adjustments we’ve all made personally and professionally in the last year are behind us, never to return. In the world of clinical research, however, some pandemic-necessitated adjustments are proving to be more than emergency stopgap measures to ensure trial continuity — and numerous decentralized clinical trial (DCT) tools and methodologies employed within the last year are likely here to stay as part of biopharma’s new normal.

Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company.

The filgotinib disaster didn’t warrant a mention as Galapagos laid out its Darwinian restructuring plans. Forced to make choices, the company is ditching its IPF molecule ’1205, while moving ahead with a Phase II IPF study for its chitinase inhibitor ’4617.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Angela Merkel (AP Photo/Michael Sohn)

Covid-19 roundup: Pfiz­er sub­mits vac­cine for full ap­proval; Merkel op­pos­es Biden pro­pos­al to sus­pend IP for vac­cines

Pfizer and BioNTech said Friday that they’ve submitted a biologics license application to the FDA for full approval of their mRNA vaccine for those over the age of 16.

How long it will take the FDA to decide on the BLA will be set once it’s been formally accepted by the agency.

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, previously told Endpoints News that the review of the BLA should take between three and four months, but it may be even faster than that.

Stéphane Bancel, Getty

Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Moderna is definitively more concerned with keeping pace with Pfizer in the race to vaccinate the world against Covid-19 than it is with Wednesday’s decision from the Biden administration to back an intellectual property waiver that aims to increase vaccine supplies worldwide.

In its first quarter earnings call on Thursday, Moderna CEO Stéphane Bancel shrugged off any suggestion that the newly US-backed intellectual property waiver would impact his company’s vaccine or bottom line. Still, the company’s stock price fell by about 9% in early morning trading.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

An­oth­er failed tri­al for Or­p­hazyme's 'pipeline-in-a-pro­duc­t' leaves shad­ow on drug's fu­ture

The tumultuous ride for Orphazyme continued on Friday as the company announced that a pivotal trial for its lead drug arimoclomol failed yet again, this time in the treatment of ALS, seeding doubt in a drug that had recently been cleared by the FDA for priority review. The latest failure casts a darker shadow on the upcoming decision despite Orphazyme’s upbeat outlook.

In a statement, the Danish biotech announced that the drug did not meet its primary or secondary endpoints evaluating function and survival. But the company has not announced any data surrounding the failure, instead saying that it will publish the complete results later this year.

In­cyte ponies up $12M to set­tle char­i­ty foun­da­tion kick­back claims; US ex­er­cis­es op­tion for more dos­es of mon­key­pox vac­cine

One in a string of lawsuits targeting copay charity foundations, the DOJ has been hunting drugmaker Incyte for what prosecutors alleged was a kickback scheme to court patients. Now, Incyte is clearing its name.

Incyte will shell out $12.6 million to settle claims it funneled funds through a charity foundation to cover federal copays for patients taking its JAK inhibitor Jakafi, the DOJ said this week.

CEO Khurem Farooq (Gyroscope)

Hours be­fore ex­pect­ed de­but, Gy­ro­scope post­pones its IPO as 2 oth­er biotechs hold the line on their march to Nas­daq

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

In a surprising turn of events, UK-based Gyroscope Therapeutics has postponed its IPO mere hours before it was set to debut on Nasdaq.

Working on a gene therapy for wet AMD, Gyroscope was all set and ready to go public earlier this week, setting terms for a $142 million raise with a price range of $20 to $22. But in the wee hours of Friday morning, the company put out a press release saying they would delay their debut “in light of market conditions,” CEO Khurem Farooq said in a statement.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

EMA safe­ty com­mit­tee seeks more in­fo on heart in­flam­ma­tion fol­low­ing Pfiz­er Covid-19 vac­cine

The European Medicines Agency’s safety committee said Friday that it’s aware of cases of inflammation of the heart muscle and inflammation of the membrane around the heart, mainly reported following vaccination with Pfizer’s Covid-19 vaccine, known in Europe as Comirnaty.

“There is no indication that these cases are due to the vaccine,” the EMA’s Pharmacovigilance Risk Assessment Committee said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

AstraZeneca’s closely-watched POSEIDON study continues to be the rare bright spot in its push for an in-house PD-L1/CTLA-4 combo.

Combining Imfinzi and tremelimumab with physicians’ choice of chemotherapy helped patients with stage IV non-small cell lung cancer live longer, the company reported — marking the first time the still-experimental tremelimumab has demonstrated an OS benefit.

For AstraZeneca and CEO Pascal Soriot, the positive readout — which is devoid of numbers — offers much-needed validation for the big bet they made on Imfinzi plus tremelimumab, after the PD-L1/CTLA-4 regimen failed multiple trials in head and neck cancer as well as lung cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.